Clinical Chemistry Analyzers Global Market Report 2024

The clinical chemistry analyzers market size has grown strongly in recent years. It will grow from $14.29 billion in 2023 to $15.2 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The expansion observed in the historical period can be attributed to factors such as the increasing aging population, prevalence of diseases and diagnostics, automation in laboratories, rising healthcare expenditure, and the demand for point-of-care testing.

The clinical chemistry analyzers market size is expected to see strong growth in the next few years. It will grow to $19.49 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. The anticipated expansion in the forecast period can be linked to factors such as the integration of artificial intelligence (AI), increased applications in personalized medicine, growing awareness of preventive healthcare, advancements in point-of-care molecular diagnostics, and the growth of emerging markets. Key trends expected in the forecast period encompass the adoption of lab-on-a-chip technology, the incorporation of real-time monitoring capabilities, initiatives towards environmental sustainability, the enhancement of interoperability with electronic health records, and the development of virtual clinical chemistry analyzer platforms.

The anticipated growth in the clinical chemistry analyzer market is driven by the increasing prevalence of infectious and chronic disorders in the foreseeable future. Infectious diseases are caused by pathogens, harmful substances entering the body through food or contact with an infected person. Chronic diseases, lasting three months or more and worsening over time, also contribute to the rising incidence. This surge in infectious and chronic disorders is fueling the demand for clinical chemistry analyzers, crucial tools for analyzing specimen samples to diagnose and manage diseases. For example, data from Johns Hopkins University in September 2022 revealed that in 2021, over 353,000 COVID-19-related fatalities were documented, surpassing the 352,000 cases reported in 2020. Consequently, the increasing incidence of infectious and chronic disorders remains a significant driver for the clinical chemistry analyzer market.

The anticipated growth in the clinical chemistry analyzer market is also attributed to the rise in healthcare expenditure in the coming years. Healthcare expenditure denotes the total amount of money spent on healthcare goods and services within a specific timeframe, typically expressed in monetary terms. The global increase in healthcare spending, particularly in emerging economies, is fostering the acquisition of advanced diagnostic equipment, including clinical chemistry analyzers. As an illustration, data from the CIHI in November 2022 projected that total health spending in Canada is expected to increase by 0.8% from $328 billion in 2021 to $331 billion in 2022. Therefore, the upward trajectory of healthcare expenditure remains a driving force for the clinical chemistry analyzer market.


A prominent trend gaining momentum in the clinical chemistry analyzer market is product innovation. Key companies in this market are focusing on developing groundbreaking products to enhance their market presence. For example, in July 2022, EDAN Instruments Inc., a China-based manufacturing company specializing in clinical chemistry analyzers and diagnostic tools, introduced the i20, a unique Point-of-Care (POC) fluorescence-based CO-OX blood gas and chemistry analysis device. Unveiled at the 74th American Association for Clinical Chemistry Annual Scientific Meeting and Clinical Laboratory Exposition (2022 AACC), the i20 boasts approximately 45 parameters, covering blood gases, electrolytes, and CO-oximetry. This innovative method aims to reduce workload in specific patient care settings such as neonatal intensive care units, critical care units, pulmonary units, hospital emergency rooms, and operating rooms. The technology's photoluminescent biosensor significantly enhances accuracy and stability while eliminating the need for space, personnel training, and maintenance.

Major players in the clinical chemistry analyzer market are directing their efforts toward the development of compact testing systems. Compact testing systems are generally small, portable, and efficient diagnostic or analytical systems for various tests or assays. For instance, in July 2023, Siemens Healthineers, a Germany-based healthcare solutions provider, announced the launch of the 'Atellica CI Analyzer' for clinical chemistry testing and immunoassays. This analyzer ensures consistency in reagents, consumables, and intelligent software for both independent laboratories and satellite labs within larger healthcare networks.

In May 2022, Quidel Corporation, a US-based manufacturer of clinical chemical analyzers and diagnostic equipment, completed the acquisition of Ortho Clinical Diagnostics Holdings plc for approximately $6.0 billion, forming QuidelOrtho Corporation, an in vitro diagnostics firm. This acquisition positions Quidel Corporation as a market leader in diagnostics, bringing together innovative products, methods, and services that mutually benefit and enhance patient health and well-being worldwide. Ortho Clinical Diagnostics Holdings plc, a US-based manufacturer of clinical chemistry analyzers and in vitro diagnostics, is a key part of this strategic move.

Major companies operating in the clinical chemistry analyzers market report are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthcare GmbH, Shenzhen Jusmooth Medical Instruments Co. Ltd., Rayto Life and Analytical Sciences Co. Ltd., Grifols S.A., Mindray Medical International Limited, Beckman Coulter Inc., Endress+Hauser Group Services AG, Sysmex Corporation, Horiba Ltd., Nova Biomedical Corporation, Biobase Group, Tecan Group Ltd., Randox Laboratories Ltd., Hitachi High-Technologies Corporation, EKF Diagnostics Holdings plc, ELITech Group Clinical Systems, SenTec AG, DiaSys Diagnostic Systems GmbH, SNIBE Co. Ltd., Awareness Technology Inc., Bio Systems Diagnostics Pvt. Ltd., DRG Instruments GmbH, Analyticon Biotechnologies AG, SFRI Medical Diagnostics, Jokoh Co. Ltd.

North America was the largest region in the clinical chemistry analyzer market in 2023. The regions covered in the clinical chemistry analyzers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the clinical chemistry analyzers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary products within the realm of clinical chemistry analyzers encompass clinical chemistry analyzers themselves, clinical chemistry reagents, and other related items. These analyzers, designed for clinical chemistry or biochemistry assessments, scrutinize samples such as blood serum, plasma, and urine. They employ measurement techniques such as photometric and colorimetric testing, ion-selective potentiometry, and latex agglutination. The technology behind these analyzers includes both semi-automated and fully automated versions, catering to the testing needs of basic metabolic panels, electrolyte panels, liver panels, lipid profiles, renal panels, thyroid function panels, and specialty chemical tests. Various end-users, including hospitals, academic research centers, diagnostic laboratories, and others, benefit from the application of clinical chemistry analyzers.

The clinical chemistry analyzers research report is one of a series of new reports that provides clinical chemistry analyzers market statistics, including the clinical chemistry analyzers industry's global market size, regional shares, competitors with clinical chemistry analyzers market share, detailed clinical chemistry analyzers market segments, market trends and opportunities, and any further data you may need to thrive in the clinical chemistry analyzers industry. This clinical chemistry analyzers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The clinical chemistry analyzer market consists of revenues earned by entities by providing calculation of immunochemical concentration and chemical analysis of specimens. The market value includes the value of related goods sold by the service provider or included within the service offering. The clinical chemistry analyzer market also includes sales of random-access chemistry analyzers, benchtop chemistry analyzers, tabletop chemistry analyzers, floor model chemistry analyzers, primary chemistry analyzers, and blood gas or critical care analyzers, which are used in providing clinical chemistry analyzer services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.